Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged Markman hearing
Will MorphoSys win the Darzalex patent case against Janssen and Genmab?

In 2016, MorphoSys ($MOR) sued Janssen ($JNJ) and Genmab for patent infringement.  MorphoSys claims that Janssen’s anti-CD38 antibody, Darzalex®, infringes three of its patents.  The case is scheduled to go to trial in February 2019.  The stakes are big because the patents purport to cover the actual protein used in Darzalex®, which could mean material royalty rates on sales of Janssen’s drug.  What are the strengths and weaknesses of each party’s case?

Read More
Markman AdvisorsMorphoSys, $MOR, Janssen, $JNJ, Genmab, Darzalex, CD38, anti-CD38, antibody, patent, patent infringement, multiple myeloma, daratumumab, Markman hearing, Zachary Silbersher, Silbersher, Merck, GileadComment
Why was the Markman hearing cancelled in Celgene’s Revlimid® patent case against Dr. Reddy’s?

On March 23, Celgene and Dr. Reddy’s informed the Court that they jointly have resolved the single pending claim construction dispute—namely, the construction of the word “crystalline” within the two asserted polymorph patents.  What does this mean for the case?

Read More
Markman AdvisorsCelgene, Dr. Reddy's, Revlimid, polymorph, patent, Markman hearing, crystalline, amorphous Comment